@entity5 growth and @entity3 are determined by the complex interplay of factors, including those @entity5 cells and extrinsic factors associated with the @entity5 microenvironment. Our previous work demonstrated key roles for @entity22416 in the maintenance of vascular integrity and eosinophil and mast cell homing. Since both of these functions affect @entity5 development, we characterized the effect of @entity22416 ablation on @entity5 growth using the B16F1 @entity320 model. Intriguingly, we found that @entity22416 plays a biphasic role in @entity5 progression. In early growth, both subcutaneous-injected @entity5 and intravenous-injected lung metastases grew more slowly in @entity22416 (-/-) @entity19 . This correlated with abnormal vessel morphology and increased vascular permeability in these @entity19 . Bone marrow transplantation experiments confirmed that this reflects a non-hematopoietic function of @entity22416 . At later stages, subcutaneous @entity5 growth was accelerated in @entity22416 (-/-) @entity19 and surpassed growth in wildtype @entity19 . Bone marrow chimera experiments demonstrated this difference was due to a hematopoietic function for @entity22416 and, correspondingly we found @entity5 mast cell numbers in @entity22416 (-/-) @entity19 . In aggregate, our analysis reveals a novel role for @entity22416 in both early and late @entity5 growth and provides novel insights into the role of the @entity5 microenvironment in @entity5 progression.

Opposing roles for XXXX in B16 @entity320 growth alter early stage vasculature and late stage immune cell infiltration.

@entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'reduced intra-tumor', 'intrinsic to tumor', 'Tumor', 'tumors'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma'] @entity22416 :: ('12490(Tax:10090)', 'Gene') :: ['Cd34', 'CD34']
@entity22416 :: (12490(Tax:10090),Gene) :: ['CD34']
